<DOC>
	<DOCNO>NCT00485134</DOCNO>
	<brief_summary>The purpose study select safe immunogenic dose Invaplex 50 intranasal vaccine , assess protection Invaplex 50 intranasal vaccine diarrhea , dysentery , fever follow challenge Shigella flexneri 2a 2457T strain .</brief_summary>
	<brief_title>Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding Assessment Protection</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , adult , male female , age 18 45 year ( inclusive ) time enrollment . Completion review comprehension test ( achieve ≥ 70 % accuracy ) . Signed informed consent form . Available required followup period schedule clinic visit . Women : negative pregnancy test understanding ( informed consent process ) become pregnant study within two ( 2 ) month follow study completion . General Health Health problem affect study participation medical history specifically include chronic medical condition psychiatric condition , diabetes mellitus hypertension condition require chronic daily therapy would place volunteer increase risk determine study physician , current use antihypertensive medication , medication may interact pseudoephedrine event require treat rhinorrhea ) . Clinically significant abnormality physical examination . Use immunosuppressive drug corticosteroid chemotherapeutics may influence antibody development . Women currently nurse Participation research involve another investigational product ( defined receipt investigational product exposure invasive investigational device ) 30 day plan date first vaccination anytime throughout duration study . Positive blood test HBsAG , HCV , HIV1 . Clinically significant abnormality basic laboratory screening . Immunosuppressive illness IgA deficiency ( normal limit ) . Research specific Presence nasal polyp , ulcer , deviate nasal septum ( defined section 4.2 ) . History chronic sinusitis chronic/seasonal rhinitis ( defined section 4.2 ) History rhinoplasty . History reactive airway disease ( asthma ) , chronic obstructive pulmonary disease , chronic bronchitis . History Bell 's palsy . Current smoker smoker past 3 month ( 'smoker ' define daily cigarette cigar , pipe use period least 1 month ) . Regular use ( weekly often antidiarrheal , anticonstipation , antacid therapy Abnormal stool pattern ( few 3 stool per week 3 stool per day ) regular basis ; loose liquid stool occasional basis . Personal family history inflammatory arthritis . Positive blood test HLAB27 . Prior exposure Shigella History microbiologically confirm Shigella infection . Received previous experimental Shigella vaccine live Shigella challenge . Travel country Shigella enteric infection endemic ( develop world ) within two year prior dose . Occupation involve handle Shigella bacteria currently , past 3 year . Serum IgG titer ≥ 2500 Shigella LPS Additionally , subject participate stage 2 follow exclude : Are employ food handler , daycare provider work nursing home , direct care immunocompromised person , child &lt; 2 year age frail elderly . Significant abnormality preadmission screen lab hematology , serum chemistry , urinalysis EKG ( EKG volunteer ≥40 year ) , determine PI PI consultation medical monitor sponsor . Allergy ciprofloxacin ampicillin ( exclude allergic either ) . History diarrhea 2 week prior plan inpatient phase . Use antibiotic 7 day Shigella inoculation proton pump inhibitor , H2 blocker , antacid within 48 hour inoculation . Inability comply inpatient rule regulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>